<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mizoribine, an <z:chebi fb="1" ids="35705">immunosuppressive agent</z:chebi> developed and marketed in Japan, was tested in experimental keratoplasty and in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="1" pm="."><plain>The drug, 2 to 4 mg/kg of body weight, administered systemically or as 10% eyedrops five times daily, suppressed immune reaction after keratoplasty in rabbits </plain></SENT>
<SENT sid="2" pm="."><plain>It seemed effective in 18 cases including 12 regrafted eyes </plain></SENT>
<SENT sid="3" pm="."><plain>In 29 cases of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, the average recurrence rate dropped from once per month to once every three months in one year </plain></SENT>
<SENT sid="4" pm="."><plain>Mizoribine is safe, easy to use, and may be of some value by itself or in combination with other drugs in the treatment of <z:hpo ids='HP_0000554'>uveitis</z:hpo> and in the prevention of corneal graft reaction </plain></SENT>
</text></document>